UPM Pharmaceuticals has announced that as a part of a multi-tier plan to update the facility, it is currently planning to expand its Bristol plant.
This 475,000-square foot commercial manufacturing facility was acquired from Pfizer to provide large-scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules, as well as semi-solid manufacturing of creams and ointments. The facility also provides tech transfer support, pilot plant scale-up capabilities, analytical and microbial testing, as well as dedicated suites for potent compounds.
UPM announced a 10-year contract with Amerigen Pharmaceuticals to manufacture generic commercial products at the Bristol facility. With this expansion UPM is planning to add more jobs for people in the future.
UPM General Counsel John Bowles stated that the expansion has officially begun in March and is expected to be completed in three to four weeks.
“We are making an investment into the plant,” Bowles said. “We’ve had a lot of projects going on since the reacquisition and part of the construction process going now involves some specialized equipment that is going to be housed in that portion of the facility adjacent to 5th Street.”
“This is an aggressive expansion of the facility. We are putting a lot of new money into the facility. The new additions will help expand our operations, our client base, and our abilities and hopefully expand our opportunities to employ local residents going forward and increase our employment role here in Bristol,” Bowles said.
